Skip to main content
Premium Trial:

Request an Annual Quote

En Route to the $1000 Genome

Tech Review has an article on Oxford Nanopore Technologies, one of the newest next-gen sequencing companies to enter the race for the $1000 genome. Because nanopore sequencing can analyze individual strands of DNA, the process saves time and money on sample prep. "We think we're the only label-free technology out there," Gordon Sanghera says. "There's no labeling. There's no amplification. And that really does take out the bulk of what you're doing." The company has raised about $20 million in funding and hopes to keep pace with Pacific Biosciences and have a machine for sale in about two years.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.